Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Trovagene's KRAS Test; Emory's Medical EmExome

Premium

Trovagene has launched a next-generation sequencing-based assay to test for KRAS oncogene mutations by assessing the urine of metastatic cancer patients with biopsy-proven KRAS mutations in their tumor.

The assay is designed to detect the seven most prevalent mutations in the KRAS oncogene and has a lower limit of detection of .04 percent, according to the company.


Emory Genetics Laboratory has launched the Medical EmExome, an exome sequencing test with enhanced coverage off 4,600 medically relevant genes. The test will cost $6,000 or $6,700 for a trio (see story, this issue).

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.